X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs VENUS REMEDIES - Comparison Results

BIOCON     Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON VENUS REMEDIES BIOCON /
VENUS REMEDIES
 
P/E (TTM) x 41.7 -1.5 - View Chart
P/BV x 7.2 0.1 6,764.5% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 BIOCON    VENUS REMEDIES
EQUITY SHARE DATA
    BIOCON
Mar-18
VENUS REMEDIES
Mar-18
BIOCON /
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,188126 943.6%   
Low Rs30561 499.2%   
Sales per share (Unadj.) Rs68.7301.8 22.8%  
Earnings per share (Unadj.) Rs7.6-24.9 -30.4%  
Cash flow per share (Unadj.) Rs14.02.5 549.0%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.3293.3 29.4%  
Shares outstanding (eoy) m600.0012.34 4,862.2%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.90.3 3,506.1%   
Avg P/E ratio x98.9-3.8 -2,629.4%  
P/CF ratio (eoy) x53.436.7 145.4%  
Price / Book Value ratio x8.60.3 2,711.8%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,9001,154 38,819.9%   
No. of employees `0006.10.9 664.8%   
Total wages/salary Rs m9,311393 2,368.6%   
Avg. sales/employee Rs Th6,705.84,026.1 166.6%   
Avg. wages/employee Rs Th1,514.2425.0 356.3%   
Avg. net profit/employee Rs Th736.9-331.8 -222.1%   
INCOME DATA
Net Sales Rs m41,2343,724 1,107.2%  
Other income Rs m2,06223 9,164.4%   
Total revenues Rs m43,2963,747 1,155.6%   
Gross profit Rs m8,291395 2,100.1%  
Depreciation Rs m3,851338 1,138.3%   
Interest Rs m615354 173.6%   
Profit before tax Rs m5,887-275 -2,138.4%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,56932 4,965.2%   
Profit after tax Rs m4,531-307 -1,476.4%  
Gross profit margin %20.110.6 189.7%  
Effective tax rate %26.7-11.5 -232.2%   
Net profit margin %11.0-8.2 -133.3%  
BALANCE SHEET DATA
Current assets Rs m41,4862,638 1,572.8%   
Current liabilities Rs m21,4132,305 929.1%   
Net working cap to sales %48.78.9 544.4%  
Current ratio x1.91.1 169.3%  
Inventory Days Days64135 47.2%  
Debtors Days Days9446 203.3%  
Net fixed assets Rs m50,6614,871 1,040.1%   
Share capital Rs m3,000123 2,431.1%   
"Free" reserves Rs m48,8083,496 1,396.2%   
Net worth Rs m51,8083,619 1,431.5%   
Long term debt Rs m17,8981,374 1,302.2%   
Total assets Rs m99,8977,509 1,330.5%  
Interest coverage x10.60.2 4,741.5%   
Debt to equity ratio x0.30.4 91.0%  
Sales to assets ratio x0.40.5 83.2%   
Return on assets %5.20.6 816.0%  
Return on equity %8.7-8.5 -103.1%  
Return on capital %9.61.6 608.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m12,0580-   
Fx outflow Rs m7,348517 1,422.7%   
Net fx Rs m4,710-517 -911.9%   
CASH FLOW
From Operations Rs m6,621514 1,287.1%  
From Investments Rs m-6,840-123 5,556.5%  
From Financial Activity Rs m-2,397-387 619.2%  
Net Cashflow Rs m-2,6124 -62,190.5%  

Share Holding

Indian Promoters % 40.4 32.9 123.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.2 4,666.7%  
FIIs % 10.7 0.6 1,844.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 66.4 30.0%  
Shareholders   109,995 20,121 546.7%  
Pledged promoter(s) holding % 0.0 36.4 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   FULFORD INDIA  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT  SUVEN LIFESCIENCES  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Higher, Oil Prices, and Top Cues in Focus Today(Pre-Open)

Indian share markets witnessed volatility during closing hours yesterday and ended their day marginally higher.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

Sensex Nearing All-Time Highs: Stocks to Buy in this Rally(Profit Hunter)

Mar 14, 2019

The BSE Sensex is heating up. In just a few days, the benchmark index is up 3%. Is this rally sustainable? Richa finds out...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Mar 22, 2019 09:19 AM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS